the health care system is to secure the full benefits of personalized
medicine, it must provide full and fair reimbursement for new
technologies, products and services, based on market principles to the
greatest extent possible. The reimbursement system — both governmental
and private payers — must have coverage and payment policies that
support the timely adoption of new personalized medicine technologies,
including both diagnostics and therapeutics.
2004, PMC's call to action is to monitor, evaluate, and contribute to
the debate to ensure that personalized medicine is properly integrated
into reimbursement systems in the years ahead.
CMS' 2016 Preliminary Gapfill Payment Determinations
CMS' Part B Drug Payment Model Proposal
CMS PAMA Payment System
Oncology Care Model at CMS
Fair and Rational Payment for Molecular Diagnostic Tests
Reimbursement for Personalized Medicine Diagnostics
Centers for Medicare and Medicaid Services (CMS) Specialty Practitioner Payment Models
Centers for Medicare and Medicaid Services (CMS) Molecular Diagnostics Gapfill Payment Amounts
Centers for Medicare and Medicaid Services (CMS) Guidance Regarding Coverage and Evidence Development
PMC and Bridgehead International Issue Brief on European Reimbursement
PMC and Boston Healthcare Issue Brief on Reimbursement in the U.S.
PMC Payer Principles
Secretary's Advisory Committee on Genetics, Health and Society: Reimbursement Report